OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research report report published on Friday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Down 3.2 %

Shares of NASDAQ OPGN opened at $1.75 on Friday. The company has a 50-day moving average of $1.89 and a 200 day moving average of $2.79. OpGen has a 12-month low of $1.49 and a 12-month high of $9.90.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million for the quarter.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new stake in OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen at the end of the most recent quarter. 2.68% of the stock is currently owned by institutional investors.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.